GlobalData on MSN16h
Novo Nordisk plans new study for CagriSema, targets 2026 submissionCagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Newsable Asianet News on MSN26m
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
European Opportunities Trust invests in European companies offering capital growth and is managed by Devon Equity Management Ltd. The company said net asset value per share fell 8.6% to 921.66 pence ...
Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $1,100.00. The endorsement comes amid a complex narrative ...
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback